SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-114056
Filing Date
2022-11-03
Accepted
2022-11-02 17:49:14
Documents
14
Period of Report
2022-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2229513d1_8k.htm   iXBRL 8-K 35645
2 EXHIBIT 10.1 tm2229513d1_ex10-1.htm EX-10.1 1100805
6 GRAPHIC tm2229513d1_ex10-1img001.jpg GRAPHIC 2919
  Complete submission text file 0001104659-22-114056.txt   1552595

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA egrx-20221101.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE egrx-20221101_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE egrx-20221101_pre.xml EX-101.PRE 22593
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2229513d1_8k_htm.xml XML 3615
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36306 | Film No.: 221355453
SIC: 2834 Pharmaceutical Preparations